Trapani V, Patel V, Leong C-O, Ciolino H P, Yeh G C, Hose C, Trepel J B, Stevens M F G, Sausville E A, Loaiza-Pérez A I
School of Pharmaceutical Sciences, University of Nottingham, UK.
Br J Cancer. 2003 Feb 24;88(4):599-605. doi: 10.1038/sj.bjc.6600722.
The fluorinated benzothiazole analogue 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole (5F 203, NSC 703786) is a novel agent with potent and selective antitumour properties and, in the form of its L-lysylamide prodrug Phortress (NSC 710305), is a current candidate for early phase clinical studies. Previous findings have indicated that cytochrome P450 1A1 (CYP1A1) may play a role in the antitumour activity of molecules in the benzothiazole series including the nonfluorinated parent compound 2-(4-amino-3-methylphenyl)benzothiazole (DF 203, NSC 674495) (Kashiyama et al, 1999; Chua et al, 2000; Loaiza-Pérez et al, 2002). In this study, we assessed and verified that a fully functional aryl hydrocarbon receptor (AhR) signalling pathway is a necessary requisite for the induction of efficient cytotoxicity by 5F 203 in MCF-7 wild-type sensitive cells. Drug exposure caused MCF-7 sensitive cells to arrest in G(1) and S phase, and induced DNA adduct formation, in contrast to AhR-deficient AH(R100) variant MCF-7 cells. In sensitive MCF-7 cells, induction of CYP1A1 and CYP1B1 transcription (measured by luciferase reporter assay and real-time reverse transcriptase-polymerase chain reaction (RT-PCR)), and 7-ethoxyresorufin-O-deethylase (EROD) activity was demonstrated, following treatment with 5F 203. In contrast, in resistant AH(R100) cells, drug treatment did not affect CYP1A1 and CYP1B1 transcription and EROD activity. Furthermore, AH(R100) cells failed to produce either protein/DNA complexes on the xenobiotic responsive element (XRE) sequence of CYP1A1 promoter (measured by electrophoretic mobility shift assay) or DNA adducts. The data confirm that activation of the AhR signalling pathway is an important feature of the antitumour activity of 5F 203.
氟化苯并噻唑类似物2-(4-氨基-3-甲基苯基)-5-氟苯并噻唑(5F 203, NSC 703786)是一种具有强效和选择性抗肿瘤特性的新型药物,其L-赖氨酰胺前药福替雷司(NSC 710305)目前正作为早期临床研究的候选药物。先前的研究结果表明,细胞色素P450 1A1(CYP1A1)可能在苯并噻唑系列分子的抗肿瘤活性中发挥作用,包括非氟化母体化合物2-(4-氨基-3-甲基苯基)苯并噻唑(DF 203, NSC 674495)(Kashiyama等人,1999年;Chua等人,2000年;Loaiza-Pérez等人,2002年)。在本研究中,我们评估并证实,在MCF-7野生型敏感细胞中,一条功能完全正常的芳烃受体(AhR)信号通路是5F 203诱导有效细胞毒性所必需的条件。与AhR缺陷型AH(R100)变异MCF-7细胞相比,药物暴露导致MCF-7敏感细胞停滞在G(1)期和S期,并诱导DNA加合物形成。在用5F 203处理后,在敏感的MCF-7细胞中,证实了CYP1A1和CYP1B1转录的诱导(通过荧光素酶报告基因检测和实时逆转录聚合酶链反应(RT-PCR)测量)以及7-乙氧基异吩恶唑酮-O-脱乙基酶(EROD)活性。相比之下,在耐药的AH(R100)细胞中,药物处理不影响CYP1A1和CYP1B1转录以及EROD活性。此外,AH(R100)细胞未能在CYP1A1启动子的外源性反应元件(XRE)序列上产生蛋白质/DNA复合物(通过电泳迁移率变动分析测量)或DNA加合物。数据证实,AhR信号通路的激活是5F 203抗肿瘤活性的一个重要特征。